[en] The objective of this study was to describe a familial screening for AIP
mutations in the context of aggressive prolactinoma in childhood. A 12-year-old
boy, presented headaches and bilateral hemianopsia. He had adequate height and
weight for his age (50(th) percentile), Tanner stage G1 P1. His bone age was 10
years. Prolactin was 10.560 ng/mL (3-25), FSH and LH were undetectable, IGF-1,
TSH, Free T4, ACTH, and cortisol were within normal ranges. MRI showed a
pituitary macroadenoma, 5.3 X 4.0 X 3.5 cm with compression of the optic chiasm,
bilateral cavernous sinus invasion, encasement of carotids, and extension to
clivus. Surgical debulking was performed. Resistance to cabergoline was
characterized and he was submitted to two surgeries and radiotherapy.
Immunohistochemical evaluation included prolactin, ACTH, GH, FSH, LH,AIP, c-erb
B2, Ki-67, and p53. Genomic DNA was isolated from the index case and 48
relatives, PCR and sequencing were performed.A germline A195V mutation in AIP was
identified in the index case and in five asymptomatic relatives. Germline
mutations in the AIP gene may be involved in the predisposition to pituitary
adenoma formation, as cause or co-factor in pathogenesis of aggressive tumors in
young patients.
Disciplines :
Endocrinologie, métabolisme & nutrition
Auteur, co-auteur :
Naves, Luciana Ansaneli
Jaffrain-Rea, Marie-Lise
Vencio, Sergio Alberto
Jacomini, Clausimir
Casulari, Luiz
Daly, Adrian ; Université de Liège - ULiège > Département des sciences cliniques > Endocrinologie
BECKERS, Albert ; Centre Hospitalier Universitaire de Liège - CHU > Endocrinologie clinique
Langue du document :
Anglais
Titre :
Aggressive prolactinoma in a child related to germline mutation in the ARYL hydrocarbon receptor interacting protein (AIP) gene.
Titre traduit :
[es] prolactinoma agressivo na infância relacionado à mutaçào no gene da proteina ARYL hidrocarbona (AIP)
Date de publication/diffusion :
novembre 2010
Titre du périodique :
Arquivos Brasileiros de Endocrinologia e Metabologia
ISSN :
0004-2730
eISSN :
1677-8487
Maison d'édition :
Sociedade Brasileira de Endocrinologia e Metabologia, Rio de Janeiro, Brésil
Daly AF, Tichomirowa MA, Beckers A. The epidemiology and genetics of pituitary tumors. Best Pract Res Clin Endocrinol Metab. 2009;23(5):543-54. Review.
Beckers A. Higher prevalence of clinically relevant pituitary adenomas confirmed. Clin Endocrinol (Oxf). 2010;72(3):290-1.
Kane LA, Leinung MC, Scheithauer BW, Bergstralh EJ, Laws Jr ER, Groover RV, et al. Pituitary adenomas in childhood and adolescence. J Clin Endocrinol Metab. 1994;79:1135-40.
Colao A, Loche S, Cappa M, Di Sarno A, Landi ML, Sarnacchiaro F, et al. Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up. J Clin Endocrinol Metab. 1998;83(8):2777-80.
Cannavò S, Venturino M, Curtò L, De Menis E, D'Arrigo C, Tita P, et al. Clinical presentation and outcome of pituitary adenomas in teenagers. Clin Endocrinol. 2003;519-27.
Acharya SV, Gopal RA, Bandgar TR, Joshi SR, Menon PS, Shah NS. Clinical profile and long term follow up of children and adolescents with prolactinomas. Pituitary. 2009;12(3):186-9.
Verhelst J, Abs R, Maiter D, Vandeweghe M, Velkeniers B, Mockel J, et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab. 1999;84:2518-22.
Musolino NR, Passos V. Prolactinomas resistentes a agonistas dopaminérgicos: diagnóstico e manejo. Arq Bras Endocrinol Metab. 2005;49(5):641-50.
Spinks JJ, Ryan FJ. Cabergoline resistance in pediatric prolactinomas. J Pediatr Hematol Oncol. 2009;31(5):377-9.
Delgrange E, Daems T, Verhelst J, Abs R, Maiter D. Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. Eur J Endocrinol. 2009;160(5):747-52. Epub 2009 Feb 17.
Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, Raitila A, et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science. 2006;312(5777):1228-30.
Daly AF, Vanbellinghen JF, Khoo SK, Jaffrain-Rea ML, Naves LA, Guitelman MA, et al. Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J Clin Endocrinol Metab. 2007;92(5):1891-6.
Naves LA, Daly AF, Vanbellinghen JF, Casulari LA, Spilioti C, Magalhães AV, et al. Variable pathological and clinical features of a large Brazilian family harboring a mutation in the aryl hydrocarbon receptor-interacting protein gene. Eur J Endocrinol. 2007;157(4):383-91.
Daly AF, Tichomirowa MA, Beckers A. Genetic, molecular and clinical features of familial isolated pituitary adenomas. Horm Res. 2009;71 Suppl 2:116-22.
Barlier A, Vanbellinghen JF, Daly AF, Silvy M, Jaffrain-Rea ML, Trouillas J, et al. Mutations in the aryl hydrocarbon receptor interacting protein gene are not highly prevalent among subjects with sporadic pituitary adenomas. J Clin Endocrinol Metab. 2007;92(5):1952-5. Epub 2007 Feb 13.
Leontiou C, Gueorguiev M, Van der Spuy J, Quinton R, Lolli F, Hassan H, et al. The role of the AIP gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab. 2008;93(6):2390-401.
Daly AF, Tichomirowa M, Petrossians P, Jaffrain-Rea ML, Barlier A, Naves LA, et al. Clinical characteristics and therapeutic responses in patients with germ-line aip mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab. 2010;95(11):E373-83.
Jaffrain-Rea ML, Angelini M, Gargano D, Tichomirowa MA, Daly AF, Vanbellinghen JF, et al. Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications. Endocr Relat Cancer. 2009;16(3):1029-43.
Colao A, Vitale G, Cappabianca P, Briganti F, Ciccarelli A, De Rosa M, et al. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab. 2004;89(4):1704-11.
de Oliveira SK, Hoffmeister M, Gambaryan S, Muller-Esterl W, Guimaraes JA, Smolenski AP. Phosphodiesterase 2A forms a complex with the co-chaperone XAP2 and regulates nuclear translocation of the aryl hydrocarbon receptor. J Biol Chem. 2007;282:13656-63.
Vandeva S, Vasilev V, Vroonen L, Naves L, Jaffrain-Rea ML, Daly AF, et al. The Familial Pituitary Tumors, Ann Endocrinol (Paris). 2010 Oct 18. [Epub ahead of print]
Pesatori AC, Baccarelli A, Consonni D, Lania A, Beck-Peccoz P, Bertazzi PA, et al. Aryl hydrocarbon receptor-interacting protein and pituitary adenomas: a population-based study on subjects exposed to dioxin after the Seveso, Italy, accident. Eur J Endocrinol. 2008;159(6):699-703.
Toledo RA, Lourenço Jr DM, Toledo SP. Familial isolated pituitary adenoma: evidence for genetic heterogeneity. Front Horm Res. 2010;38:77-86. Epub 2010 Jul 5. Review
Jaffrain-Rea ML, Tichomirowa MA, Daly AF, Beckers A. Pituitary adenomas in young patients: when should we consider a genetic predisposition? Expert Rev Endocrinol Metab. 2009;4(6):529-31.
Blatch GL, Lassle M. The tetratricopeptide repeat: a structural motif mediating protein-protein interactions. Bioessays. 1999;21(11):932-9.
Khoo SK, Pendek R, Nickolov R, Luccio-Camelo DC, Newton TL, Massie A, et al. Genome-wide scan identifies novel modifier loci of acromegalic phenotypes for isolated familial somatotropinoma. Endocr Relat Cancer. 2009;16(3):1057-63. Epub 2009 May 14
Jaffrain-Rea ML, Di Stefano D, Minniti G, Esposito V, Bultrini A, Ferretti E, et al. A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumors: secreting versus non secreting adenomas. Endocrine Related Cancer. 2002;(9):103-13.
Levy A, Hall L, Yeudall WA, Lightman SL. P53 gene mutations in pituitary adenomas: a rare events. Clin Endocrinol (Oxf). 1994;41:809-14.
Botelho CH, Magalhães AV, Mello PA, Schmitt FC, Casulari LA. Expression of p53, Ki-67 and c-erb B2 in growth hormone-and/or prolactin-secreting pituitary adenomas. Arq Neuropsiquiatr. 2006;64(1):60-6.
Oliveira MC, Marroni CP, Pizarro CB, Lima JFP, Coutinho LMB. Expression of p53 protein in pituitary adenomas. Braz J Med Biol Res. 2002;35:561-5.
Al-Shraim M, Asa SL. The 2004 World Health Organization Classification of pituitary tumors: what is new? Acta Neuropathol. 2006;111(1):1-7 Review
